Literature DB >> 2329967

Comparative study on the pharmacokinetics of 7-hydroxy-methotrexate after administration of methotrexate in the dose range of 0.5-33.6 g/m2 to children with acute lymphoblastic leukemia.

J D Borsi1, E Sagen, I Romslo, P J Moe.   

Abstract

Concentrations of 7-hydroxy-methotrexate (7-OH-MTX) were determined in serum samples obtained after 266 infusions of methotrexate administered to 58 children with acute lymphoblastic leukemia. The dose of methotrexate (MTX) was in the range of 0.5-33.6 g/m2. Pharmacokinetic parameters (metabolic index, drug/metabolite ratio, half-life) of 7-OH-MTX and their relationship to the kinetics of methotrexate were analyzed. A great variability was observed in the extent and time-course of the metabolite formation. The concentration of the metabolite was higher than that of the parent compound at any examined time after the end of the 24 hours' infusion. The increase of 7-OH-MTX levels at the end of the methotrexate infusion was found to be proportionate to the increase of the dose of MTX. Males had significantly higher metabolite levels than did females (P less than 0.01) in the dose range of 0.5-8.0 g/m2. The age of the patients also significantly influenced the rate of the metabolite formation. The serial number of the treatment courses did not have effect on the metabolism of MTX. Dose dependency of the elimination half-life of the metabolite was found. Although a tendency was observed that patients in continuous complete remission had higher metabolite levels than those who relapsed, the difference was not significant. Further studies are needed to determine the clinical importance of 7-OH-MT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2329967     DOI: 10.1002/mpo.2950180310

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

1.  High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.

Authors:  Laila Holmboe; Anders M Andersen; Lars Mørkrid; Lars Slørdal; Kirsten Sundby Hall
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

2.  Renal and hepatic toxicity after high-dose 7-hydroxymethotrexate in the rat.

Authors:  E Smeland; R M Bremnes; A Andersen; R Jaeger; T J Eide; N E Huseby; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

3.  Inhibition of 7-hydroxymethotrexate formation by amsacrine.

Authors:  R M Bremnes; E Smeland; N P Willassen; E Wist; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

4.  High-dose 7-hydromethotrexate: acute toxicity and lethality in a rat model.

Authors:  E Smeland; O M Fuskevåg; K Nymann; J S Svendesn; R Olsen; S Lindal; R M Bremnes; J Aarbakke
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

5.  Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis.

Authors:  J E Baggott; S L Morgan; W H Vaughn
Journal:  Biochem J       Date:  1994-06-15       Impact factor: 3.857

6.  Proteinuria due to suboptimal hydration with high-dose methotrexate therapy.

Authors:  G T Kovács; C Paál; P Somló; R Koós; D Schuler; J D Borsi
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

7.  Effect of SLCO1B1 Polymorphisms on High-Dose Methotrexate Clearance in Children and Young Adults With Leukemia and Lymphoblastic Lymphoma.

Authors:  Rachael R Schulte; Leena Choi; Nipun Utreja; Sara L Van Driest; C Michael Stein; Richard H Ho
Journal:  Clin Transl Sci       Date:  2020-09-25       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.